Abstract
Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have